Curriculum vitae

Academic appointments, postdoctoral training and education

05/2015 - now Research Director, Institute of Biosciences and Applications, NCSR Demokritos, Athens, Greece

09/2015-09/2017 Visiting Professor, Department of Chemistry, University of Athens, Athens, Greece

07/2009-05/2015 Senior Investigator, Institute of Biosciences & Applications (former Institute of Biology), NCSR Demokritos, Athens, Greece

12/2005-07/2009 Investigator, Institute of Biology, NCSR Demokritos, Athens, Greece

10/2006 Visiting scientist, Dr Vassilis I. Zannis’ lab, Molecular Genetics Unit, Whitaker Cardiovascular Institute, Department of  Medicine, Boston University Medical School, Boston, MA, USA

06-11/2005 Instructor of Medicine, Boston University Medical School, Boston, MA

08/2000-06/2005 Research Assistant (Postdoctoral researcher), Dr Vassilis I. Zannis’ lab, Molecular Genetics Unit, Whitaker Cardiovascular Institute, Department of Medicine, Boston University Medical School, Boston, MA, USA

1/2005 Visiting scientist, Dr. Matti Jauhiainen’s lab, National Public Health Institute, Department of Molecular Medicine, Biomedicum, Helsinki,   Finland

07/2003 – 12/2003 Research Assistant (Postdoctoral researcher), Dr Monty Krieger’ lab, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA

10-11/2000 Visiting scientist, Dr. Arnold von Eckardstein’s lab, Institute of Clinical Chemistry and Laboratory Medicine, University of Munster, Munster, Germany

2000 Ph.D. in Chemistry, Biochemistry Laboratory, Department of Chemistry, University of Athens, Athens, Greece

6-8/1999 Visiting scientist, Dr. Dipak Ramji’ s lab, Biochemistry Unit of Cardiff School of Biosciences, Cardiff University, Cardiff, Wales, UK

1996 M.Sc. in Biochemistry, Department of Chemistry, University of Athens, Athens, Greece

1994 B.Sc. in Chemistry (first in class), Department of Chemistry, University of Athens, Athens, Greece


Scholarships/ Awards/ Honors

2020 Hellenic Society of Lipidology, Atherosclerosis and Vascular Disease research proposal award

2015 “Georgios Tsitouris” award for best research proposal, Hellenic Society of Lipidology, Atherosclerosis and Vascular Disease

2012 Hellenic Society of Lipidology, Atherosclerosis and Vascular Disease research proposal award

2010 Hellenic Society of Lipidology, Atherosclerosis and Vascular Disease research proposal award

2009 L’ORÉAL-UNESCO Greek Award for Women in Science

2005 Irvine H. Page Young Investigator Research Award Finalist, 6th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, American Heart Association, USA

2004 First Place Winner, Evans Medicine Research Days Abstract Competition, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.

2002, 2003 Research Award for poster presentation, 4th and 5th Research Symposiums of the New England Hellenic Medical and Dental Society, Boston, MA, USA.

1994 Department of Chemistry, University of Athens, Greece: Highest ranking among my graduating class

 

Supervision of research

Postdoctoral fellows

Vassiliki Skamnaki (2007-2009), Ioannis Dafnis (2012-2020), Faye Soukou (2013-2015), Maria Katsarou (2013-2016), Evgenia Megalou (2014-2015), Christina Raftopoulou (2014-2015),  Angeliki Bourtsala (2018-2019), Christina Gkolfinopoulou (2019-2022), Maria Karanikou (2020- 2021), Dafni Georgiadou (2022- ), Effie Valanti (2022- )

 

Doctoral theses

2020- Anastasia-Georgia Dedemadi, «Study of composition and function of high density lipoprotein (HDL) in pathological conditions: enhancement of atheroprotective functions of HDL by small molecules», Department of Chemistry, University of Athens

2019- Achilleas Papayannis, “Association between high density lipoprotein functionality and acute ischemic stroke severity and outcome”, Department of Medicine, Aristotle University of Thessaloniki

2017-2022 Christina Mountaki, “Role of apolipoprotein E in the pathogenesis of Alzheimer’s disease - effect of natural compounds on structure and function of apoE”, Department of Chemistry, University of Athens

2014-2019 Christina Gkolfinopoulou, “Structural and functional characterization of naturally occurring apoA-I mutants - analysis of HDL atheroprotective properties”, Department of Chemistry, University of Athens

2011-2016 Letta Argyri, “Structure-function relationship of human apolipoproteins: ApoE4 and Alzheimer’s disease”, Department of  Chemistry, University of Athens

2009-2013 Georgios Daniil, “Role of various proteins (apoA-I, cholesterol transporters, enzymes) of the high-density lipoprotein (HDL) pathway”, Department of Chemistry, University of Athens

2007-2011 Ioannis Dafnis, “Structure-function relationship of apolipoprotein E in brain”, Department of Chemistry, University of Athens


Master theses

2022-            Dimitris Lymberopoulos,«Effect of naturally occurring compounds on paraoxonase 1 activity», Interdepartmental Postgraduate Program "Clinical Biochemistry-Molecular Diagnostics", University of Athens

2020-2022 Asimina Micha, «Relationship between apolipoprotein E4 and lipid transport in the brain with Alzheimer's disease», Interdepartmental Postgraduate Program "Clinical Biochemistry-Molecular Diagnostics", University of Athens

2017-2019 Konstantina Katrini, “Analysis of the antioxidant propertierties of HDL from patients that suffered acute ischemic stroke and association of HDL antioxidant properties with the severity and outcome of stroke”, Department of Chemistry, University of Athens

2016-2017 Christina Mountaki, “Role of apolipoprotein E isoforms in regulation of neuronal cholesterol efflux and amyloid-beta peptide generation”, Department of Chemistry, University of Athens

2011-2014 Christina Gkolfinopoulou, “Role of hydrophobic amino acid residues located in the carboxyl-terminus of apolipoprotein A-I on protein’s structure and function”, Department of Chemistry, University of Athens

2007-2009 Georgios Daniil, “Analysis of Composition and Functions of HDL from Patients with Familial Low and High HDL Syndromes. Study of Interactions of  Apolipoprotein A-I with the ABCG1 Cholesterol Transporter”, Department of Chemistry, University of Athens

2006-2007 Georgios Michas, “Analyses of HDL composition and functions in Greek patients who survived myocardial infarction before the age of 36 years and in mouse models”, School of Medicine, University of  Crete


Diploma theses

2022-2023 Eirini Georgiou, “Study of brain PON1 activity in the mouse model of Alzheimer's disease 5xFAD in relation to the age of mice and Corinthian raisin diet”, Department of Chemistry, University of Athens

2021-2022 Lydia Voulgari, “Study of serum PON1 activity in the mouse model of Alzheimer's disease 5xFAD in relation to the age of mice and Corinthian raisin diet”, Department of Chemistry, University of Athens 

2017-2018 Christiana Moutzouvi, "Expression of the bioengineered apoE4 mutant apoE4[R189A] and analysis of the effect of mutation on the structure and function of  apoE4." Department of Chemistry, University of Athens

2016 Angeliki Letsiou, “Expression and purification of recombinant human apolipoprotein A-I - Examination of the amyloidogenic propensity of the natural occurring  apolipoprotein A-I point mutant apoA-I[A164S] that is associated with increased risk for myocardial infraction.” Department of Chemistry, University of Athens

2016 Nefeli Boni-Kazantzidou, “Expression and purification of recombinant human apolipoprotein E3 - Examination of the amyloidogenic propensity of natural occurring apolipoprotein E3 point mutants associated with lipoprotein glomerulopathy.” Department of Chemistry, University of Athens

2012 Dionyssis Yannimaras, Chrissa Nikolopoulou, “Expression and purification of recombinant human apolipoprotein A-I. Effect of proinflammatory factor PAF in cholesterol efflux from proadipocytes.” Department of Chemistry, University of Athens

2011 Christina Golfinopoulou, Christos Balis, “Effect of proinflammatory factors in cholesterol efflux from macrophages.” Department of Chemistry, University of  Athens

2008-2009 Alexia Phedonos, “Role of lipids and lipid metabolism proteins in atherosclerosis and Alzheimer’s disease. Analyses of composition and properties of HDL  obtained from family subjects carrying ABCA1 mutations.” Department of Biology and Biochemistry, University of Bath, UK



Teaching experience and related activities

2018 - now Member of the Inter-Departmental Committee and faculty in the joined MSc Programme “Applied Biochemistry: Clinical Chemistry, Biotechnology, Evaluation of Pharmaceutical Products” of the Department of Chemistry of the University of Patras and of the Institute of Biosciences and Applications of NCSR Demokritos. Courses: Biochemical Analysis - Clinical Biochemistry, Molecular & Cellular Biology

2019 - now Guest lecturer in graduate course “Clinical Biochemistry”, “Clinical Chemistry-Molecular Diagnostics” Graduate Program, Faculties of Biology, Chemistry and Nursing and Medical School, University of Athens

2015-2017 Visiting Professor, Main Instructor of the undergraduate course “Biochemistry I” (6th semester), 26h of lectures, 180 students, Department of Chemistry, University of Athens, Greece

2010-2018 Guest lecturer in graduate course “Clinical Chemistry II”, “Clinical Chemistry” Graduate Program, Department of Chemistry, University of Athens

2008-2014 Guest lecturer in graduate course “Human Biochemistry”, “Biochemistry” Graduate Program, Department of Chemistry, University of Athens

2013 Guest lecturer in the 2nd semester of Graduate Program “Molecular and Applied Physiology”, School of Medicine, University of Athens

2013 Guest lecturer in the graduate Program “Applied Nutrition and Dietetics”, Department of Nutrition and Dietetics, Harokopio University

2008 Guest lecturer in graduate course “Chemistry and Biochemistry of Lipids”, “Biochemistry” Graduate Program, Department of Chemistry, University of Athens

1995-1999 Teaching Assistant, Department of Chemistry, University of Athens, Greece

2009 - now Member of 8 PhD Thesis Examination Committees; Member of 7 Msc Thesis Examination Committees

2010 - now   Person in charge for education issues in the Institute of Biosciences and Applications (IBE). Member of the Education Committee of NCSR Demokritos

2007-2010 Member of the Education Committee, Institute of Biology, NCSR Demokritos

2006-2007 Member of the Fellowship Examination Committee for graduate students, Institute of Biology, NCSR Demokritos

2009 Instructor for the graduate course “Cell signaling”, Institute of Biology, NCSR Demokritos

2011 Lecturer in 1st Summer School “Proteins: from gene to structure and beyond…” organized by the Department of Biology, University of Athens

2006, 2008-2010, 2012, 2014-2019, 2021 Lecturer in annual Summer School organized by NCSR Demokritos on current advances in natural sciences and technology.



Other Academic and Outreach Activities

2022- Editorial board member, Atherosclerosis Plus, Elsevier

2022-         Associate editor, Frontiers in Cardiovascular Medicine - Lipids in Cardiovascular Disease

2022-        Associate editor, Frontiers in Genetics

2021 Presentation about my research career and activities in the event GLOBAL WOMEN’S BREAKFAST “Women in Science: Empowering Diversity in Science” organised by IUPAC and the Department of Chemistry of the University of Athens, 9 February 2021

2020 Lecture entitled “Contacting literature search in biosciences (Peer-reviewed literature vs “grey” literature, PUBMED, Google Scholar databases) - Information on NCBI databases” presented during the Laboratory workshop for secondary school teachers, organised by the Institute of Biosciences and Applications of NCSR “Demokritos” and the European Learning Laboratory for the Life Sciences (ELLS) of European Molecular Biology Laboratory (EMBL), 11-13 September 2020, Athens, Greece

2019 Member of the Organizing Committee of the Insulin-Regulated Aminopeptidase IRAP 2019 international meeting, 27-30 August 2019, Nafplio, Greece

2018 Lecture entitled “Molecular mechanisms of atherosclerosis and Alzheimer’s disease”, presented during the “Women in Science Classes” meeting organized by L’Oreal Hellas and Hellenic National Commission for UNESCO in the context of the 20th anniversary of the international programme L’Oreal-Unesco “For women in Science”, 22 September 2018, Athens

2017 Member of the Organizing Committee of the 68th Congress of the Hellenic Society of Biochemistry and Molecular Biology, 10-12 November 2017, Athens

2014 Host for a Short Term Scientific Mission under COST Action ΒΜ0904 for Ms Milica Miljkovic, University of Belgrade, Servia. Topic of visit: Training on assays for the analysis of HDL subpopulations.

2013 Host for a Short Term Scientific Mission under COST Action ΒΜ0904 for Dr. Jelena Kotur-Stevuljevic, University of Belgrade, Servia. Topic of visit: Training on the analysis of antiatherogenic properties of HDL.

2011 Organization of 1st Working Groups meeting of COST Action ΒΜ0904 “HDL: From Biological Understanding to Clinical Exploitation”, 28-29 January 2011, Athens

2010-2011    Lead Guest Editor, Special Issue on “Lipids and lipoproteins in atherosclerosis”, Journal of Lipids

 

Member of Institutional and other Committees

2020 - now Member of Special Committee for Research Utilization, NCSR Demokritos

2016-2018 Member of the Scientific Board of IBA

2011-2014 Member of the Scientific Advisory Board of IBA

2010 - now Member of the Education Committee of NCSR Demokritos

2006 - now   Member of several Committees of NCSR Demokritos (selection of external partners, contract acceptance, tender evaluation for electronic οpen international  equipment procurement, evaluation of objections and appeals for public procurement tenders)

2015 – now           Member of several Evaluation Committees for the recruitment or promotion of Researchers or University Teaching and Research Staff 

2020 - now   Alternate Member of the General Assembly of the Hellenic Foundation for Research and Innovation

 


Participation in Scientific Organizations

2020-                Hellenic Society for Neuroscience

2018-                Hellenic Crystallographic Association

2014-                European Atherosclerosis Society

2007-                Hellenic Atherosclerosis Society.

2012-                Member of the Management Committee of Working Group on the Pathophysiology of Atherosclerosis, Hellenic Atherosclerosis Society

2020-2021        Vice-Chairman of the Management Committee of Working Group on the Pathophysiology of Atherosclerosis, Hellenic Atherosclerosis Society

2022-                Chairman of the Management Committee of Working Group on the Pathophysiology of Atherosclerosis, Hellenic Atherosclerosis Society

2005-                Hellenic Society of Lipidology, Atherosclerosis and Vascular Disease

2004-2006        American Heart Association/ Council on Arteriosclerosis, Thrombosis and Vascular Biology

1996-                Hellenic Society of Biochemistry and Molecular Biology

 


Invited presentations

1)        Recombinant protein expression in E.coli: Options, Approaches and Paradigms, 4th CAPSTONE-ETN Summit, 19-21 October 2022, Athens

2)   a) HDL cholesterol: Reassessment of its clinical significance. b) The role of apolipoprotein E in lipid homeostasis in circulation and tissues. Webinar series on "Atherosclerosis and Cardiovascular disease" organized in the framework of ELIDEK project entitled “Lifestyle and cardiovascular disease: From pathophysiological mechanisms to clinical practice” (CARDIOLIFE), 22 September 2022

3)        Inflammation and Atherosclerosis: from pathophysiology to therapeutic interventions. 15th  Summer School of the Hellenic Atherosclerosis Society. 1-2 July 2022, Athens

4)      Quantity or quality? The myth of "good" cholesterol. Joint Seminar Series in Biotechnology, Biosciences and Biomedical Research organized by the University Research Center of Ioannina (Institute of Biosciences), the Foundation for Research and Technology-Hellas (Biomedical Research Institute) and the Inter-institutional Interdepartmental Program of Postgraduate Studies in Molecular and Cellular Biology and Biotechnology, 15 April 2022, Ioannina

5)    HDL-Cholesterol: Reassessing its Clinical Significance. Webinar series on "Mechanisms of induction and progression of atherosclerosis - Recent data" organized by the Working Group on Pathophysiology of Atherosclerosis of the Hellenic Atherosclerosis Society, 30 March 2020

6)   Elucidation of the relationship between apolipoprotein A-I/HDL and cardiovascular risk. Athenian Days of Lipidology, Atherosclerosis and Vascular Disease, 3-5 October 2019, Athens

7)     Apolipoprotein E structural properties: insights into function and pathogenesis of human diseases.  9th International Conference of the Hellenic Crystallographic Association, 5-7 October 2018, Patra

8)      HDL-cholesterol: reappraisal of its clinical significance. 7th Meeting of the working groups of the Hellenic Atherosclerosis Society, 1-2 December 2017, Athens.

9)        Alzheimer’s disease and apolipoprotein E gene: risk and mechanisms for disease development. Seminar series, NCSR Demokritos, 6 December 2016, Athens.

10)   HDL: From the understanding of its biological role to the clinical use for the diagnosis and treatment of cardiovascular disease and other diseases. 6th Meeting of the working groups of the Hellenic Atherosclerosis Society, 4-5 December 2015, Athens

11)    Implication of apoE4 at the early events of Alzheimer’s disease: clues from structure and function analysis of apoE4 proteolytic fragments and hereditary mutations. 2014 Seminar Series, Center of clinical research, experimental surgery and translational research, Biomedical Research Foundation of the Academy of Athens, 21 May 2014, Athens.

12)    Study of apoE4 mutations as a tool for understanding Alzheimer’s disease pathogenesis. Department of Biochemistry and Biotechnology, University of Thessaly, 14 May 2014, Larissa.

13)   HDL atheroprotective properties: quantity, quality and therapeutic approaches. 5th Meeting of the working groups of the Hellenic Atherosclerosis Society, 29-30 November 2013, Athens

14)    Disorders of HDL metabolism pathway: causes and clinical phenotypes. Round table on “Newer developments in genetics of cardiovascular disease”, 16th Meeting of the Hellenic Society of Lipidology, Atherosclerosis and Vascular Disease, 3-5 October 2013, Athens.

15)   The role of apolipoprotein E in the pathogenesis of human diseases (type III hyperlipoproteinemia, lipoprotein glomerulopathy, Alzheimer’s disease). Seminar series, Institute of Biology, Medicinal Chemistry & Biotechnology, National Hellenic Research Foundation, February 13, 2013, Athens.

16)   Unraveling the connection between apolipoprotein E and Alzheimer’s disease. 63rd Congress of the Hellenic Society of Biochemistry and Molecular Biology, November 9 2012, Heraklio Crete.

17)   Molecular basis of the role of apolipoprotein E in the pathogenesis of Alzheimer’s disease. Invited speaker seminar series, University of Patras Medical School, April 4, 2012, Patra.

18)    The role of apolipoprotein E in the pathogenesis of Alzheimer’s disease. Seminar Series, Chemistry Department, University of Athens, February 8, 2010, Athens.

19)    Carboxy-terminal truncated apolipoprotein E4 promotes intracellular accumulation of amyloid peptide beta 42 in neuronal cells. International symposium to honor Professor Emeritus Vassilis I. Zannis, University of Crete Medical School, October 16, 2009, Herakleio.

20)   Molecular mechanisms of high-density lipoprotein (HDL) biosynthesis: Lessons learned from gene transfer studies in mouse models. 30th Hellenic Society for Biological Sciences Congress, May 22-24, 2008, Thessaloniki.

21)   Molecular mechanisms of high-density lipoprotein (HDL) biosynthesis and plasma lipid homeostasis. Round table on “Pathophysiology of Atherosclerotic Disease”, 2nd Meeting of the working groups of the Hellenic Atherosclerosis Society, November 30-December 1, 2007, Athens.

22)  Lipids and lipoproteins: From atherosclerosis to Alzheimer’s disease. Round table on «Biological Chemistry of Cardiovascular System», CARDIO Athena 2007, International Meeting on Cadiovascular Medicine, March 16-17, 2007, Athens.

23)   Role of apoA-I in the biogenesis of HDL and in lipid homeostasis. Round table on «Obesity, Metabolic Syndrome and Cardiovascular Disease», 10th Meeting of the Hellenic Society of Lipidology and Atherosclerosis, May 26-27, 2006, Athens.

24)  Molecular mechanisms of apolipoproteins A-I and E role in dyslipidemia, atherogenesis and Alzheimer’s disease. Seminar series, Institute of Radioisotopes and Radiodiagnostic Products, NCSR “Demokritos”, May 4, 2006, Athens.


Peer-reviewed publications

70) Papagiannis A., Gkolfinopoulou C., Tziomalos K., Dedemadi A. G., Polychronopoulos G., Milonas D., Savopoulos C., Hatzitolios A. I. and Chroni A. HDL cholesterol efflux capacity and phospholipid content are associated with the severity of acute ischemic stroke and predict its outcome. Clin. Chim. Acta 540, 117229 (2023)

69) Loch R. A., Wang H., Perálvarez-Marín A., Berger P., Nielsen H., Chroni A. and Luo J. Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases. Comput. Struct. Biotechnol. J. 21, 1189-1204 (2023)

68) Dafnis I., Mountaki C., Fanarioti E., Mastellos D. C., Karvelas M., Karathanos V. T., Tzinia A., Dermon C. R. and Chroni A. Temporal Pattern of Neuroinflammation Associated with a Low Glycemic Index Diet in the 5xFAD Mouse Model of Alzheimer's Disease. Mol. Neurobiol. 59, 7303-7322 (2022).

67) Dafnis I., Tsouka A. N., Gkolfinopoulou C., Tellis C. C., Chroni A. and Tselepis A. D. PCSK9 is minimally associated with HDL but impairs the anti-atherosclerotic HDL effects on endothelial cell activation. J. Lipid Res. 63, 100272 (2022).

66) Valanti E. K., Dalakoura-Karagkouni K., Fotakis P., Vafiadaki E., Mantzoros C. S., Chroni A., Zannis V., Kardassis D. and Sanoudou D. Reconstituted HDL-apoE3 promotes endothelial cell migration through ID1 and its downstream kinases ERK1/2, AKT and p38 MAPK. Metabolism 127, 154954 (2022).

65) Chroni A., Thymiakou E. and Kardassis D. Genetics and regulation of HDL metabolism. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 1867, 159060 (2022).

64) Mountaki C., Dafnis I., Panagopoulou E. A., Vasilakopoulou P. B., Karvelas M., Chiou A., Karathanos V. T. and Chroni A. Mechanistic insight into the capacity of natural polar phenolic compounds to abolish Alzheimer's disease-associated pathogenic effects of apoE4 forms. Free Radic. Biol. Med. 171, 284-301 (2021).

63) Gkolfinopoulou C., Soukou F., Dafnis I., Kellici T. F., Sanoudou D., Mavromoustakos T., Stratikos E. and Chroni A. Structure-function analysis of naturally occurring apolipoprotein A-I L144R, A164S and L178P mutants provides insight on their role on HDL levels and cardiovascular risk. Cell. Mol. Life Sci. 78, 1523-1544 (2021).

62) Chroni A., Rallidis L., Vassou D., Gkolfinopoulou C., Papakosta P., Zervou M.I., Goulielmos G.N., Kiouri E, Pappa D., Eliopoulos E. and Kardassis D. Identification and characterization of a rare variant in apolipoprotein A-IV, p.(V336M), and evaluation of HDL functionality in a Greek cohort with extreme HDL cholesterol levels. Arch Biochem. Biophys. 696, 108655 (2020).

61) Gkolfinopoulou C., Bourtsala A. and Chroni A. Structural and functional basis for increased HDL-cholesterol levels due to the naturally occurring V19L mutation in human apolipoprotein A-I. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 1865, 158593 (2020).

60) Kavetsou E., Katopodi A., Argyri L., Chainoglou E., Pontiki E., Hadjipavlou-Litina D., Chroni A. and Detsi A. Novel 3-aryl-5-substituted-coumarin analogues: Synthesis and bioactivity profile. Drug Dev. Res. 81, 456-469 (2020).

59) Divolis G., Stavropoulos A., Manioudaki M., Apostolidou A., Doulou A., Gavriil A., Dafnis I., Chroni A., Mummery C., Xilouri M. and Sideras P. Activation of both TGFβ and BMP signaling pathways upon traumatic brain injury restrains pro-inflammatory and boosts tissue reparatory responses of reactive astrocytes and microglia. Brain Commun.1, fcs028 (2019).

58) Tziomalos K., Katrini K., Papagianni M., Christou K., Gkolfinopoulou C., Angelopoulou S.M., Sofogianni A., Savopoulos C., Hatzitolios A.I. and Chroni A. Impaired antioxidative activity of high-density lipoprotein is associated with more severe acute ischemic stroke. Metabolism 98, 49-52 (2019).

57) Valanti E.K., Chroni A. and Sanoudou D. The future of apolipoprotein E mimetic peptides in the prevention of cardiovascular disease. Curr. Opin. Lipidol. 30, 326-341 (2019).

56) Chroni A.* and Kardassis D.* HDL dysfunction caused by mutations in apoA-I and other genes that are critical for HDL biogenesis and remodelling. Curr. Med. Chem. 26, 1544-1575 (2019).  * corresponding author

55) Katsarou M., Stratikos E. and Chroni A. Thermodynamic destabilization and aggregation propensity as the underlying mechanism behind the genetic association of apoE3 mutants and Lipoprotein Glomerulopathy. J. Lipid Res., 59, 2339-2348 (2018).

54) Nissilä E., Hakala P., Leskinen K., Roig A., Syed S., van Kessel K. P. M., Metso J., de Haas C. J. C., Saavalainen P., Meri S., Chroni A., van Strijp  J. A. G., Öörni K., Jauhiainen M., Jokiranta T. S. and Haapasalo K. Complement Factor H and Apolipoprotein E Participate in Regulation of Inflammation in THP-1 Macrophages. Front. Immunol. 9:2701/ doi: 10.3389/fimmu.2018.02701 (2018).

53) Dafnis I., Argyri L. and Chroni A. Amyloid-peptide β 42 enhances the oligomerization and neurotoxicity of apoE4: the C-terminal residues Leu279, Lys282 and Gln284 modulate the structural and functional properties of apoE4. Neuroscience 394, 144-155 (2018).

52) Bourtsala A., Dafnis I. Chroni A., Farmaki T. and Galanopoulou D. Study of the involvement of phosphatidic acid formation in the expression of wound-responsive genes in cotton. Lipids 53, 589-599 (2018).

51) Dafnis I., Raftopoulou C., Mountaki C., Megalou E., Zannis V. I. and Chroni A. ApoE isoforms and carboxyl-terminal truncated apoE4 forms affect neuronal BACE1 levels and Aβ production independently of their cholesterol efflux capacity. Biochem J. 475, 1839-1859 (2018).

50) Prasinou P., Dafnis I., Giacometti G., Ferreri C., Chroni A. and Chatgilialoglu C. Fatty acid-based lipidomics and membrane remodeling induced by apoE3 and apoE4 in human neuroblastoma cells. Biochim. Biophys. Acta Biomembr., 1859, 1967-1973 (2017)

49) Kavetsou E., Gkionis L., Galani G., Gkolfinopoulou C., Argyri L., Pontiki E., Chroni A., Hadjipavlou-Litina D. and Detsi A. Synthesis of prenyloxy coumarin analogues and evaluation of their antioxidant, lipoxygenase (LOX) inhibitory and cytotoxic activity. Med. Chem. Res., 26, 856–866 (2017).

48) Dafnis I., Argyri L., Sagnou M., Tzinia A., Tsilibary E. C., Stratikos E. and Chroni A. The ability of apolipoprotein E fragments to promote intraneuronal accumulation of amyloid beta peptide 42 is both isoform and size-specific. Sci. Rep. 6:30654 / DOI: 10.1038/srep30654 (2016).

47) Dafnis I., Metso J., Zannis V. I., Jauhiainen J. and Chroni A. Influence of isoforms and carboxyl-terminal truncations on the capacity of apolipoprotein E to associate with and activate Phospholipid Transfer Protein. Biochemistry, 29, 5855-66 (2015).

46) Ljunggren S.A., Levels J.H., Hovingh K., Holleboom A.G., Vergeer M., Argyri L., Gkolfinopoulou C., Chroni A., Sierts J.A., Kastelein J.J., Kuivenhoven J.A., Lindahl M., Karlsson H. Lipoprotein profiles in human heterozygote carriers of a functional mutation P297S in scavenger receptor class B1. Biochim. Biophys. Acta, 1851, 1587-95 (2015).

45) Haapasalo K., van Kessel K., Nissilä E., Metso J., Johansson T., Miettinen S., Varjosalo M., Kirveskari J., Kuusela P., Chroni A., Jauhiainen M., van Strijp J., Jokiranta T.S. Complement Factor H Binds to Human Serum Apolipoprotein E and Mediates Complement Regulation on High Density Lipoprotein Particles. J. Biol. Chem., 290, 28977-87 (2015).

44) Tiniakou I., Georgopoulos S., Chroni A., van Eck M., Fotakis P., Zannis V.I. and Kardassis D. Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice. Atherosclerosis, 243, 77-85 (2015).

43) Gkolfinopoulou C., Stratikos E., Theofilatos D., Kardassis C., Voulgari P.V., Drosos A.A. and Chroni A. Impaired antiatherogenic functions of high-density lipoprotein in patients with ankylosing spondylitis. J. Rheumatol., 42, 1652-60 (2015).

42) Favari E., Chroni A., Uwe JF Tietge U. J. F., Zanotti I., Escolà-Gil J. C., Bernini F. Cholesterol efflux and reverse cholesterol transport. Handb. Exp. Pharmacol., 224, 181-206 (2015).

41) Davalos A.* and Chroni A.* Antisense oligonucleotides, microRNAs and antibodies. Handb. Exp. Pharmacol., 224, 649-89 (2015). * corresponding author

40) Zannis V. I., Fotakis P., Koukos G., Kardassis D., Ehnholm C., Jauhiainen J. and Chroni A. HDL biogenesis and remodeling. Handb. Exp. Pharmacol., 224, 53-111 (2015).

39) Zvintzou E., Skroubis G., Chroni A., Petropoulou P. I., Gkolfinopoulou C., Sakellaropoulos G., Gantz D., Mihou I., Kalfarentzos F. and Kypreos K. E. Effects of bariatric surgery on HDL structure and functionality: results from a prospective trial. J Clin Lipidol., 8, 408-17 (2014).

38) Fotakis P., Vezerides A., Dafnis I., Chroni A., Kardassis D. and Zannis V. I. ApoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL. J. Lipid Res., 55, 1310-1323 (2014).

37) Argyri L., Dafnis I., Theodossiou T. A., Gantz D., Stratikos E. and Chroni A. Molecular basis for increased risk for late-onset Alzheimer's disease due to the naturally occurring Leu28Pro mutation in apolipoprotein E4. J. Biol. Chem., 289, 12931-45 (2014).

36) Stratikos E. and Chroni A.  A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy. Clin. Exp. Nephrol., 18, 225-229 (2014).

35) Fotakis P., Tiniakou I., Kateifides A. K., Gkolfinopoulou C., Chroni A., Stratikos E., Zannis V. I. and Kardassis D. Significance of the hydrophobic residues 225 to 230 of apoA-I for the biogenesis of HDL. J. Lipid Res., 54, 3293-302 (2013).

34) Fotakis P., Kateifides A. K., Gkolfinopoulou C., Georgiadou D., Beck M., Gründler K., Chroni A., Stratikos E., Kardassis D. and Zannis V. I. Role of the hydrophobic and charged residues in the 218 to 226 region of apoA-I in the biogenesis of HDL. J. Lipid Res., 54, 3281-92 (2013).

33) Daniil G., Zannis V. I. and Chroni A. Effect of apoA-I mutations in the capacity of reconstituted HDL to promote ABCG1-mediated cholesterol efflux. PLoS ONE, 8(6), e67993 (2013).

32) Georgiadou D., Chroni A., Drosatos K., Kypreos K. E., Zannis V. I. and Stratikos E. Allele-dependent thermodynamic and structural perturbations in ApoE variants associated with the correction of dyslipidemia and formation of spherical ApoE-containing HDL particles. Atherosclerosis, 226, 385-391 (2013).

31) Georgiadou D., Stamatakis K., Efthimiadou E., Kordas G., Gantz D., Chroni A.* and Stratikos E.* Thermodynamic and structural destabilization of apolipoprotein E3 by hereditary mutations associated with the development of Lipoprotein Glomerulopathy. J. Lipid Res., 54, 164-176 (2013).                          * corresponding author

30) Holleboom A. G., Daniil G., Fu X., Zhang R., Hovingh G. K., Schimmel A. W., Kastelein J. J. P., Stroes E. S. G., Witztum J. L., Hutten B. A., Tsimikas S., Hazen S. L., Chroni A. and Kuivenhoven J. A. Lipid Oxidation in Carriers of Lecithin:Cholesterol Acyltransferase Gene Mutations. Arterioscler Thromb Vasc Biol, 32, 3066-3075 (2012).

29) Dafnis I., Tzinia A., Tsilibary E. C., Zannis V. I. and Chroni A. An apolipoprotein E4 fragment affects MMP9, TIMP1 and cytokine levels in brain cell lines. Neuroscience, 210, 21-32 (2012).

28) Georgiadou D., Chroni A., Vezerides A., Zannis V. I. and Stratikos E. Biophysical analysis of apolipoprotein E3 mutants linked with development of Type III Hyperlipoproteinemia. PLoS ONE, 6(11), e27037 (2011).

27) Argyri L., Skamnaki V., Stratikos E. and Chroni A. A simple approach for human recombinant apolipoprotein E4 expression and purification. Prot. Express. Purif., 79, 251-257 (2011).

26) Besler C., Heinrich K., Rohrer L., Doerries C., Riwanto M., Shih D. M., Chroni A., Yonekawa K., Stein S., Schaefer N., Mueller M., Akhmedov A., Daniil G., Manes C., Templin C., Wyss C., Maier W., Tanner F.C., Matter C. M., Corti R., Furlong C., Lusis A.J., von Eckardstein A., Fogelman A. M., Lüscher T. F., Landmesser U. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest., 121, 2693-2708 (2011).

25) Vezerides A., Chroni A. and Zannis V. I. Domains of apoE4 required for the biogenesis of apoE-containing HDL. Ann. Med., 43, 302-311 (2011).

24) Kateifides A. K., Gorshkova I. N., Duka A., Chroni A., Kardassis K. and Zannis V.I Alteration of negatively charged residues in the 89 to 99 domain of αpoA-I affects lipid homeostasis and the maturation of HDL. J. Lipid Res., 52, 1363-1372 (2011).

23) Daniil G., Phedonos A. A. P., Holleboom A. G., Motazacker M. M., Argyri L., Kuivenhoven J. A. and Chroni A. Characterization of antioxidant/anti-inflammatory properties and apoA-I-containing subpopulations of hdl from family subjects with monogenic low HDL disorders. Clin. Chim. Acta, 412, 1213-1220 (2011).

22) Ohnsorg P. M., Rohrer L., Perisa D., Kateifides A., Chroni A., Kardassis D., Zannis V. I. and von Eckardstein A. Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not pre-lipidated ApoA-I particles through aortic endothelial cells. J. Biol. Chem., 286, 7744-7754 (2011).

21) Georgiadou D., Hearn A., Evnouchidou I., Chroni A., Leondiadis L., York, I. A., Rock K. L. and Stratikos E. Placental Leucine Aminopeptidase Efficiently Generates Mature Antigenic Peptides In Vitro but in Patterns Distinct from Endoplasmic Reticulum Aminopeptidase 1. J. Immunol., 185(3):1584-1592 (2010).

20) Dafnis I., Stratikos E., Tzinia A., Tsilibary E. C., Zannis V. I. and Chroni A. An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42, J. Neurochem., 115, 873-884 (2010).

19) Evnouchidou E., Momburg F., Papakyriakou A., Chroni A., Leondiadis L., Chang S.- C., Goldberg A. L. and Stratikos E. The internal sequence of the peptide-substrate determines its N-terminus trimming by ERAP1. PLoS ONE, 3, e3658 (2008).

18) Chroni A.*, Pyrpassopoulos S., Thanassoulas A., Nounesis G., Zannis V. I. and Stratikos E.*, Biophysical analysis of progressive C-terminal truncations of human apolipoprotein E4: insights into secondary structure and unfolding properties. Biochemistry, 47, 9071-9080 (2008).   * corresponding author 

17) Zannis V. I., Koukos G., Drosatos K., Vezerides A., Zanni E. E., Kypreos K. E. and Chroni A. Discrete Roles of ApoA-I and ApoE in the Biogenesis of HDL Species: Lessons Learned from Gene Transfer Studies in Different Mouse Models. Ann. Med., 40, 14–28 (2008).

16) Koukos G, Chroni A., Duka A., Kardassis D. and Zannis V. I. LCAT can rescue the abnormal phenotype produced by the natural apoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN. Biochemistry, 46, 10713-10721 (2007).

15) Koukos G, Chroni A., Duka A., Kardassis D. and Zannis, V. I. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected with treatment with LCAT. Biochem. J., 406, 167-174 (2007).

14) Chroni A.*, Koukos G., Duka A. and Zannis V I. The carboxy-terminal region of apoA-I is required for the ABCA1-dependent formation of a-HDL but not preb-HDL particles in vivo. Biochemistry, 46, 5697-5708 (2007). * corresponding author

13) Singaraja R. R., Visscher H., James E. R., Chroni A., Coutinho J. M., Brunham L. R., Kang M. H., Zannis V. I., Chimini G., and Hayden M. R. Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro. Circ. Res., 99, 389-397 (2006).

12) Zannis V. I., Chroni A., and Krieger M. Role of apoA-I, ABCA1 and SR-BI in the biogenesis of HDL, J. Mol. Med., 84, 276-294 (2006).

11) Gorshkova I. Ν, Liu T., Kan H. Y., Chroni A., Zannis V. I and Atkinson D. Structure and stability of apolipoproteinA-I in solution and in discoidal High-Density Lipoprotein probed by double charge ablation and deletion mutation. Biochemistry, 45, 1242-1254 (2006).

10) Chroni A., Duka A., Kan H. Y., Liu T. and Zannis V. I. Point mutations in apoA-I mimic the phenotype observed in patients with classical LCAT deficiency. Biochemistry, 44, 14353-14366 (2005).

9) Chroni A., Nieland T. F. J., Kypreos K. E., Krieger M. and Zannis V. I SR-BI mediates cholesterol efflux via its interactions with lipid-bound apoE. Structural mutations in SR-BI diminish cholesterol efflux. Biochemistry, 44, 13132-13143 (2005).

8) Chroni A., Kan H. Y., Shkodrani A., Liu T. and Zannis V. I. Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-deficient mice. Biochemistry, 44, 4108-4117 (2005).

7) Chroni A., Kan H. Y., Kypreos K. E., Gorshkova, I. Ν, Shkodrani A. and Zannis V. I. Substitutions of Glu110, Glu111 in the middle helix 4 of apoA-I by Ala affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice. Biochemistry, 43, 10442-10457 (2004).

6) Nieland T. F. J., Chroni A., Fitzgerald M. L., Maliga Z., Zannis V. I, Kirchhausen T. and Krieger M. Cross-inhibition of SR-BI and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and Glyburide. J. Lipid Res., 45, 1256-1265 (2004).

5) Zannis V. I., Chroni A., Kypreos K. E., Kan H. Y., Borges Cesar T., Zanni E. E. and Kardassis D. Probing the pathways of chylomicron and HDL metabolism using adenovirus mediated gene transfer. Curr. Opin. Lipidol., 15, 151-166 (2004).

4) Chroni A., Liu T., Fitzgerald M. L., Freeman M. W. and Zannis V. I. Cross-linking and lipid efflux properties of apoA-I mutants suggest direct association between apoA-I helices and ABCA1. Biochemistry, 43, 2126-2139 (2004).

3) Fitzgerald M. L., Morris A. L., Chroni A., Mendez A. J., Zannis V. I. and Freeman M. W. ABCA1 and amphipathic apolipoproteins form high affinity molecular complexes required for cholesterol efflux. J. Lipid Res, 45, 287-294 (2004).

2) Chroni A., Liu T., Gorshkova I., Kan H. Y., Uehara Y., von Eckardstein A. and Zannis V. I. The central helices of apoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220-231 of the wild-type apoA-I are required for lipid efflux in vitro and HDL formation in vivo. J. Biol. Chem., 278, 6719-6730, (2003).

1) Chroni A. and Mavri-Vavayanni M. Characterization of a platelet-activating factor acetylhydrolase from rat adipocytes. Life Sciences, 67, 2807-2825 (2000).

 


Book chapters/editorials


Funding